Biohaven Pharmaceuticals is a biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting the glutamatergic system and other neurological pathways. Biohaven has licensed intellectual property from Yale University and several pharmaceutical companies. NYSE: BHVN